Combining liver cancer treatments doubles survival rates, UVA resear...( Charlottesville Va. April 15 2008 B...),Health
Charlottesville, Va., April 15, 2008 By combining the use of stents and photodynamic therapy, also called SpyGlass, physicians at the University of Virginia have been able to significantly increase survival rates for patients suffering from advanced cholangiocarcinoma, cancer of the liver bile duct.
Most patients who develop this type of cancer cannot have surgery as it is diagnosed at such a late stage, so there was not much we could do except offer them palliative care, said University of Virginia Gastroenterologist Michel Kahaleh, M.D., lead investigator of the study. By combining therapies, we saw an improved survival rate from just more than 7 months to more than 16 months.
In the study, recently published in the March 2008 issue of Clinical Gastroenterology and Hepatology, 48 patients were treated with advanced cholangiocarcinoma over a five year period. Twenty-nine patients were treated with biliary stents, with the remaining 19 being treated with the stents and photodynamic therapy (PDT). The stents decompress the bile ducts, maintaining liver function. The combined therapy group received treatment every three months, at which time all stents were replaced.
The combined therapy group had survival rates of 16.2 months compared to the stent-only groups 7.4 months. Mortality rates in the group that received PDT was 0, 16, and 56 percent at three, six, and 12 months respectively. Mortality rates in the stent-only group were 28, 52, and 82 percent respectively. Kahaleh said the number of stent-replacement procedures and PDT sessions were the only factors which significantly impacted survival.
Photodynamic Therapy treatment uses a photosensitizing agent (porfimer sodium in this study) which is activated using light of a specific wavelength, which then kills the targeted cells. PDT has been used for more than a decade to destroy cancer cells and reduce tumor size.
Cancer of the liver bile ducts is the second most common
'/>"/>
| Contact: David Foreman daf4n@virginia.edu 434-924-2242 University of Virginia Health System Source:Eurekalert |
Related medicine news :
1. Combining Internet With Office Visits Cut Heart Attack Risks
2. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
3. Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis
4. In blood vessel stents, innovative materials allow better control, delivery of gene therapy
5. New Treatments Help Fight Liver, Colon Cancer
6. Health Care Work Force Too Small, Unprepared for Aging Baby Boomers; Higher Pay, More Training, and Changes in Care Delivery Needed to Avert Crisis
7. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
8. New technique in treating patients with liver cancer proves effective
9. Mayo Clinic identifies treatment target for liver cancer recurrence and survival
10. New York Cigarette Tax Increase Delivers Victory for Kids and Taxpayers
11. Two Liver Cancer Treatments Better Than One
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |